Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDaraxonrasib and Elironrasib

Plus 6 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 3, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?9 U.S. locations

Locations may change over time.

Who runs it?Revolution Medicines, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Revolution Medicines, Inc.
Interventions being studied: Drug: Daraxonrasib; Drug: Elironrasib; Drug: Zoldonrasib; Drug: Ivonescimab; Drug: Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only); Drug: cetuximab (Cohort C2 Only); Drug: Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only); Drug: Daraxonrasib (Cohort B1 only)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

At least 18 years old and has provided informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.
Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration).
Non-squamous NSCLC without a treatable driver mutation in other oncogenes that has not received prior systemic treatment (Arms A \& B for Part 2 Dose Expansion).
Solid tumor or CRC previously treated with no more than 2 prior lines of therapy for advanced disease and progressed or been intolerant to prior standard therapies (Arm C for Part 2 Dose Expansion).
Measurable disease per RECIST v1.1
Adequate organ function (bone marrow, liver, kidney, coagulation, endocrine).
Able to take oral medications.

Reasons someone may not be able to joinExclusion criteria

Head and neck squamous cell carcinoma.
Any conditions that may affect the ability to take or absorb study drug.
Major surgery within 4 weeks prior to receiving study drug(s).
Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Other inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

USC Norris Comprehensive Cancer CenterLos Angeles, California
Eastern Connecticut Hematology and Oncology AssociatesNorwich, Connecticut
Health Partners Cancer Center at Regions HospitalSaint Paul, Minnesota
Tennessee OncologyNashville, Tennessee
MD Anderson Cancer CenterHouston, Texas
MD Anderson Cancer CenterHouston, Texas
NEXT DallasIrving, Texas
NEXT OncologySan Antonio, Texas
NEXT VirginiaFairfax, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 3, 2026. Always confirm current availability with the study team.

View original record ↗